Acknowledgments
der
DER, HILDENBRAND
We thank all patients and donors who participated in the TOL-1 phase I trial.We also thank Ulrike Gern, Mandy Hinkelbein, Alexander Kunz, Stefanie Mechler, Birgit Michels, Dr. Brigitte Neuber, Petra Richter (GMP Core Facility), Dr. Volker Eckstein (FACS Core Facility), Sandra Kräker, Renate Schulz (Chimerism Laboratory) of the Department of Hematology, Sibylle Bassauer, Anja Brüchig, Marita Heilke, Tina Hildenbrand, Marzena Kirschke, Martina Kutsche-Bauer, Marion Miltz-Savidis, Olga Ochs, Silja Petersen-Nowag, Regina Seemuth of the Institute of Immunology, Iris Arnold, Sabine Böhnisch-Schmitt, Gabriela Lange, Ute von der Emde, Anke Wollschläger of the Department of Nephrology (all at Heidelberg University Hospital, Heidelberg, Germany), and Dr. Petra Pavel at the Institute for Clinical Transfusion Medicine and Cell Therapy (Heidelberg, Germany).We thank Prof. Dr. Peter Schnülle, Nierenzentrum Weinheim, Weinheim, Germany and Prof. Dr. Frieder Keller, Division of Nephrology, University Hospital Ulm, Ulm, Germany for data safety monitoring during the TOL-1 Study phase.We thank Dr. Phil Halloran from Alberta Transplant Applied Genomics Centre (ATAGC), University of Alberta, Edmonton, AB, Canada for critical advice.